~~<i id='FB4C88E8FB'><strike id='FB4C88E8FB'><tt id='FB4C88E8FB'><pre id='FB4C88E8FB'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：focus 2025-09-06 09:54:34 Page View：84141

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Pediatricians' group reaffirms support for gender
Next article： In Memoriam: Notable people who died in 2023

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

A controversial new treatment promises to make little people taller

AhminHaider(center)andhisbrotherBelalHaider(right)workontheirhomeworkwiththeircousinZayyanAgboatwall

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

0:33VanessaBryantsharedaphototoherInstagramaccountofherdaughterBiankaBryanthuggingTaylorSwiftduringa

WSS

focus

focus

knowledge

leisure time

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert